NEW YORK, NY--(Marketwire - Mar 5, 2013) -  Two biotechnology companies, NASDAQ's Celgene, Corp. and Nuvilex, Inc. (OTCQB: [ NVLX ]), are hot on the heels of a third biotech that has dominated the pancreatic drug market since 1996. Stock House Group, a research and content development investor relations firm, takes a look at the amazing results that both are delivering and tells a story that the NYSE's Eli Lilly and Company should start giving a little more attention.

In late January, those with advanced stage pancreatic cancer received some good news when Celgene, Corp., an international biotechnology company, announced the results of its large scale phase III trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), held in San Francisco. 

Pancreatic cancer is difficult to diagnose and treat until it is at an advanced stage. Survival of patients with advanced, inoperable pancreatic cancer is usually only several weeks or a few months. The National Cancer Institute estimates that, in the U.S. alone, 45,220 new cases of pancreatic cancer will be diagnosed in 2013 and that 38,460 deaths will be attributable to the dreaded disease this year.

But, like two prize fighters, a pair of biotech companies, is steadfast in the battle against a common enemy -- pancreatic cancer. Both have presented astounding results that leave one to think, we may be extremely close to turning the corner in the fight against this brutal disease.

David and Goliath Strengthen Hand vs. Opponent
One is a Goliath in the biotech world, leaving the other to take on the role of David as a much smaller biotech, but for those who suffer with pancreatic cancer, they don't see size, they see results. And, the results these two companies are delivering are providing much needed hope to patients, interestingly though, from two completely different approaches.

Read the full feature news article at [ www.stockhousegroup.com/features ]

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we are building a library of Research for Investors to use while doing their due diligence on micro, small and large cap stocks.